Blend Components Record · Four Ledger Folios
Inside the KLOW Stack: The Four Peptides
Four distinct molecules filed as four separate ledger entries under one shelfmark. Each constituent's identity, mechanism, and study record catalogued independently.
In plain English
The KLOW stack contains four peptides — four short chains of amino acids — that were each discovered and studied separately. They are mixed together in one research vial, but they do not fuse into a single molecule. Think of it as four separate ingredients that stay separate even after you combine them.
KPV is three amino acids long and focuses on calming inflammation. GHK-Cu is also three amino acids long but carries a copper ion, and its main research area is collagen and tissue repair. BPC-157 is fifteen amino acids long and has been studied extensively in rodent models of tendon and muscle injury. TB-500 is seven amino acids long and is linked to cell movement and wound closure — though most of the strong data belong to a longer version of the same protein, not this short fragment.
The four are present in the vial at different amounts: 50 mg of GHK-Cu, and 10 mg each of BPC-157, TB-500, and KPV, for a total of 80 mg. GHK-Cu is more than half the vial by weight.
KPV — the anti-inflammatory arm
Folio: KPV — Lysine-Proline-Valine. The C-terminal residues 11-13 of alpha-MSH (alpha-melanocyte-stimulating hormone, a 13-amino-acid regulatory peptide). Linear tripeptide L-Lys-L-Pro-L-Val. Molecular weight: 342.44 Da. CAS: 67727-97-3. Share of canonical vial: 10 mg.
KPV's primary mechanism is inhibition of NF-kappaB nuclear import — blocking the master inflammatory transcription factor from entering the cell nucleus — and suppression of MAPK ERK/p38 signaling, with downstream reductions in TNF-alpha, IL-6, IL-1beta, and IL-8 secretion in epithelial and immune cells [3]. The key pharmacology is PepT1 (SLC15A1) — a di/tripeptide transporter expressed in intestinal epithelium at a Km of approximately 160 micromolar for KPV that is upregulated in inflamed mucosa, giving KPV preferential uptake at sites of active gut inflammation [3]. In mouse colitis models (DSS- and TNBS-induced), oral KPV at 100 micromolar in drinking water reduced inflammation severity.
No controlled KPV monotherapy trial has reached human approval. Human clinical data is restricted to delivery pilots and a lineage in inflammatory bowel disease research.
GHK-Cu — the matrix and copper arm
Folio: GHK-Cu — Glycyl-L-Histidyl-L-Lysine Copper(II) complex (Copper Tripeptide-1). Naturally occurring tripeptide Gly-His-Lys chelated 1:1 to a Cu(II) ion. Molecular weight: 402.92 Da. CAS: 89030-95-5. Share of canonical vial: 50 mg — approximately 62.5% by mass, the dominant component.
First isolated from human plasma by Loren Pickart in 1973; plasma levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [4]. GHK-Cu is the best-characterized topical cosmetic and wound-healing peptide in the blend, with decades of human skin data. It stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and decorin, and in placebo-controlled comparisons, topical GHK-Cu improved collagen production in 70% of women versus 50% for vitamin C [4]. At the genome level, GHK modulates approximately 31.2% of human protein-coding genes at the 50%-or-greater change threshold, with strongest signals on extracellular-matrix, ubiquitin-proteasome, DNA-repair, and antioxidant gene sets [5].
Copper delivered by GHK-Cu is a cofactor for lysyl oxidase, the enzyme responsible for crosslinking collagen and elastin into load-bearing connective tissue. Caution: the dominant copper load in the vial warrants consideration for anyone with a copper-handling disorder (such as Wilson's disease).
BPC-157 — the angiogenic repair arm
Folio: BPC-157 — Body Protection Compound 157, also PL 14736. Synthetic 15-amino-acid peptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight: 1419.53 Da. CAS: 137525-51-0. Share of canonical vial: 10 mg.
BPC-157 was originally developed as PL 14736 for inflammatory bowel disease. Its primary research mechanism is activation of the VEGFR2/PI3K/Akt/eNOS cascade (vascular endothelial growth factor receptor 2, which drives angiogenesis and nitric-oxide production) and upregulation of the growth-hormone receptor in tendon fibroblasts. In transected-Achilles studies, doses as small as 10 picograms per rat accelerated healing across biomechanical, functional, and microscopic measures [2]. BPC-157 also rescued corticosteroid-impaired muscle healing [8], improved crush-injury muscle recovery [9], and supported bone healing in a rabbit segmental defect model [10]. A 2022 review documented protective effects across striated, smooth, and cardiac muscle in rodents [11].
BPC-157 was placed by the FDA in Category 2 of the 503A bulk-substances review — meaning it cannot be used as an active ingredient in compounded human-use formulations by 503A pharmacies. Human data: a 2025 IV safety pilot in two adults found no adverse events [6] — a two-subject, open-label, non-efficacy report.
TB-500 — the cytoskeletal migration arm
Folio: TB-500 — Ac-LKKTETQ, an N-acetylated heptapeptide. Synthetic fragment corresponding to the LKKTET actin-binding motif of native thymosin beta-4 (Tbeta4, a 43-amino-acid protein). Molecular weight: 889.02 Da. CAS: not assigned for the fragment. Share of canonical vial: 10 mg.
The LKKTET motif sequesters G-actin (monomeric globular actin) — a step linked to cell migration and re-epithelialization. The foundational biochemistry establishing this interaction was characterized in 1992 in muscle and platelet actin [12]. Full-length native thymosin beta-4 additionally activates integrin-linked kinase and mobilizes epicardial progenitors — activities established for the native protein, not for the short TB-500 fragment.
Most cited wound-healing and tissue-repair efficacy data — including the +42%/+61% re-epithelialization figures in rat wound models [1] — were generated with full-length Tbeta4. The fragment carries the actin-sequestration mechanism but the rest of the native protein's activity profile is not assumed to transfer automatically. TB-500 (thymosin beta-4) is on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition [7].